TRACON Pharmaceuticals, Inc.

TCON

US89237H3084

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.81 ^USD	+1.12%		-7.65%	-48.32%

Apr. 03	TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned	CI
Mar. 06	HC Wainwright Adjusts Price Target on TRACON Pharmaceuticals to $6 From $7, Keeps Buy Rating	MT

TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 05, 2024 at 05:01 pm EST

TRACON Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 12.05 million. Net loss was USD 3.59 million compared to USD 29.14 million a year ago.

Basic loss per share from continuing operations was USD 2.2 compared to USD 27.8 a year ago. Diluted loss per share from continuing operations was USD 2.2 compared to USD 27.8 a year ago.

Latest news about TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned	Apr. 03	CI
HC Wainwright Adjusts Price Target on TRACON Pharmaceuticals to $6 From $7, Keeps Buy Rating	Mar. 06	MT
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Transcript : TRACON Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 05, 2024	Mar. 05
Earnings Flash (TCON) TRACON PHARMACEUTICALS Reports Q4 Revenue $3M, vs. Street Est of $1.5M	Mar. 05	MT
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 05	CI
TRACON Pharmaceuticals, Inc. Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial	Dec. 20	CI
Tracon Licenses Product Development Platform for $3 Million Upfront Payment; Shares Jump	Nov. 20	MT
TRACON Pharmaceuticals, Inc. Announces License of Product Development Platform for $3.0 Million Upfront Payment	Nov. 20	CI
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks	Nov. 10	MT
Exchange-Traded Funds, Equity Futures Rise After Fed Chief's Comments	Nov. 10	MT
Investors Parse Powell Remarks as US Futures Advance Slightly in Friday Trading	Nov. 10	MT
Top Premarket Gainers	Nov. 10	MT
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Transcript : TRACON Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
TRACON Pharmaceuticals, Inc. Announces Resignation of Bonne Adams as Chief Operating Officer, Effective October 15, 2023	23-10-06	CI
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned	23-09-18	CI
North American Morning Briefing : Stock Futures -2-	23-08-22	DJ
JonesTrading Downgrades TRACON Pharmaceuticals to Hold From Buy	23-08-21	MT
Baird Trims Price Target on TRACON Pharmaceuticals to $3 From $7, Maintains Outperform Rating	23-08-15	MT
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Transcript : TRACON Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 14, 2023	23-08-14
TRACON Pharmaceuticals, Inc.(NasdaqCM:TCON) dropped from Russell 3000E Growth Index	23-06-23	CI
TRACON Pharmaceuticals, Inc.(NasdaqCM:TCON) dropped from Russell 3000E Index	23-06-23	CI
TRACON Pharmaceuticals, Inc.(NasdaqCM:TCON) dropped from Russell Microcap Growth Index	23-06-23	CI

Chart TRACON Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Companyâs clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.81 USD

Average target price

37.5 USD

Spread / Average Target

+1,971.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
TRACON PHARMACEUTICALS, INC.	-48.32%	4.12M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals